FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:121-122 July 13, 1995 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Two recent studies have suggested that amiodarone, a potent antiarrhythmic agent, is a promising drug for the treatment of ventricular tachyarrhythmias after myocardial infarction.^1,2 The results of two additional studies of the use of amiodarone after myocardial infarction (the European Myocardial Infarct Amiodarone Trial and the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial) will soon be reported.^3,4

In this issue of the Journal, Singh and his coworkers report the results of the Veterans Affairs Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.⁵ This trial examined the effect of amiodarone on mortality in patients with chronic congestive heart failure and 10 . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kovoor, P., Eipper, V., Byth, K., Cooper, M.J., Uther, J.B., Ross, D.L. (1999). Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur Heart J 20: 364-374 [Abstract]  
• Sim, I., McDonald, K. M., Lavori, P. W., Norbutas, C. M., Hlatky, M. A. (1997). Quantitative Overview of Randomized Trials of Amiodarone to Prevent Sudden Cardiac Death. Circulation 96: 2823-2829 [Abstract] [Full Text]  
• Silver, M. J., Young, J., Topol, E. J., Colli, A., Sechi, L. A., De Carli, S., Bartoli, E., Singh, S. N., Fletcher, R. D., Fisher, S. G. (1995). Amiodarone in Congestive Heart Failure. NEJM 333: 1639-1641 [Full Text]  
• (1995). Amiodarone Improves CHF Symptoms But Not Mortality Rates. Journal Watch Cardiology 1995: 10-10 [Full Text]